Key Takeaways
- • Crystalys Therapeutics closed an oversubscribed $130 million Series B financing led by Frazier Life Sciences, with participation from 19 institutional investors including Wellington Management, HBM Healthcare Investments, and Soleus Capital.
- • The capital will fund late-stage global clinical development and commercialization preparation for dotinurad, a once-daily oral URAT1 inhibitor designed to treat gout with best-in-class safety and efficacy potential.
- • The round achieved oversubscription status, indicating strong institutional demand for the company's gout therapeutic platform despite competitive market dynamics.
- • All existing investors participated in the round, signaling confidence in the program's advancement and de-risking from earlier-stage development milestones.
Summary
Crystalys Therapeutics, a San Diego-based clinical-stage biopharmaceutical company, announced the closing of its $130 million Series B financing on July 27, 2026. The round was oversubscribed, demonstrating robust institutional appetite for the company's pipeline focused on addressing unmet medical needs in gout treatment.
The financing was led by Frazier Life Sciences and attracted participation from a diversified consortium of life sciences investors. Key participants included Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, and KCap Biotechnology Fund. All existing investors—including Novo Holdings, SR One, Catalys Pacific, Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, abrdn-managed funds, KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners, and Prebys Ventures Fund—reinvested in the round, representing a validation of earlier investment theses.
The capital will support advancement of dotinurad, Crystalys' lead asset, through late-stage global clinical development and commercialization preparation. Dotinurad is characterized as a next-generation, once-daily oral URAT1 inhibitor designed to deliver best-in-class safety and efficacy for gout treatment. The positioning against existing therapeutic options suggests Crystalys is targeting a competitive market with meaningful clinical differentiation. The oversubscribed nature of the funding round reflects institutional confidence in the program's clinical trajectory and commercial potential within the gout treatment landscape.
The financing was led by Frazier Life Sciences and attracted participation from a diversified consortium of life sciences investors. Key participants included Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, and KCap Biotechnology Fund. All existing investors—including Novo Holdings, SR One, Catalys Pacific, Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, abrdn-managed funds, KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners, and Prebys Ventures Fund—reinvested in the round, representing a validation of earlier investment theses.
The capital will support advancement of dotinurad, Crystalys' lead asset, through late-stage global clinical development and commercialization preparation. Dotinurad is characterized as a next-generation, once-daily oral URAT1 inhibitor designed to deliver best-in-class safety and efficacy for gout treatment. The positioning against existing therapeutic options suggests Crystalys is targeting a competitive market with meaningful clinical differentiation. The oversubscribed nature of the funding round reflects institutional confidence in the program's clinical trajectory and commercial potential within the gout treatment landscape.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.